Wockhardt has set an ambitious timeline for securing European regulatory approval for its pharmaceutical product Zaynich, targeting July 2026 as the completion date for this critical milestone.

Regulatory Timeline and Strategic Focus

The company's announcement regarding Zaynich reflects its strategic approach to international market expansion. The July 2026 target date provides a clear timeline for stakeholders and demonstrates the company's commitment to navigating the European regulatory landscape.

Market Expansion Strategy

The European approval timeline represents a significant component of Wockhardt's broader international expansion strategy. Securing regulatory approval in European markets would potentially open new revenue streams and strengthen the company's global pharmaceutical presence.

Regulatory Pathway Forward

The targeted July 2026 approval date suggests that Wockhardt is actively engaged in the regulatory submission and review process with European authorities. This timeline indicates the company's confidence in meeting the stringent requirements set by European regulatory bodies for pharmaceutical product approvals.

Wockhardt Limited has received an upgraded ESG (Environmental, Social, and Governance) rating of 73 (Excellent) for 2025 from ESG Risk Assessments & Insights Limited, a SEBI-registered ESG rating provider. This represents a significant improvement from the company's previous ESG rating of 67.3 received for Financial Year 2024-25. The pharmaceutical company disclosed this latest information to stock exchanges on January 1, 2026, in compliance with regulatory requirements.

Latest ESG Rating Assessment

The new rating assignment was conducted voluntarily by ESG Risk Assessments & Insights Limited as part of their ESG assessment process. Similar to the previous rating, the company has clarified that it did not engage the rating provider for this purpose, making it an unsolicited assessment.

Rating Methodology and Independence

ESG Risk Assessments & Insights Limited determined the rating independently based on Wockhardt's public disclosures and other publicly available information. The rating provider conducted its assessment without any direct engagement or commissioning from the company, ensuring an objective evaluation of the pharmaceutical company's ESG practices and performance.

Regulatory Compliance and Disclosure

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. This regulatory framework mandates listed companies to inform exchanges about ESG ratings received from SEBI-registered providers.

The company has made this information available on its official website at www.wockhardt.com , ensuring transparency and accessibility for stakeholders. Company Secretary Rashmi Mamtura signed the regulatory filing dated January 1, 2026, with reference number WOCK/SEC/SE/2025-26/058, confirming the authenticity of the disclosure.